SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 19, 2004
CuraGen Corporation
(Exact name of registrant as specified in its charter)
| | | | |
| Delaware | | 0-23223 | | 06-1331400 |
(State or other jurisdiction of incorporation) | | (Commission File Number) | | (IRS Employer Identification No.) |
555 Long Wharf Drive, 11th Floor
New Haven, Connecticut 06511
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (203) 401-3330
Item 5. Other Events and Regulation FD Disclosure.
On May 19, 2004, 454 Life Sciences (“454”), a majority-owned subsidiary of CuraGen Corporation, announced that 454 has received a two-year, $2.4 million grant titled “Massively Parallel High Throughput, Low Cost Sequencing” from the National Human Genome Research Institute (NHGRI), one of the National Institutes of Health (NIH). The grant, for next generation whole genome picoliter-scale sequencing technology, will help fund the scale up of 454’s technology toward sequencing of larger genomes.
A copy of the press release is attached to this Current Report on Form 8-K asExhibit 99.1.
Item 7. Financial Statements and Exhibits.
(c) The following exhibit is filed with this report:
| | |
Exhibit Number
| | Description
|
| 99.1 | | Press release of Registrant dated May 19, 2004. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | |
| | | CURAGEN CORPORATION |
| | | (Registrant) |
| | |
| Date: May 20, 2004 | | By: | | /s/ David M. Wurzer
|
| | | Name: | | David M. Wurzer |
| | | Title: | | Executive Vice President and Chief Financial Officer |
